Nerea Gómez de San José
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Nerea Gómez de San José has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
- Steffen Halbgebauer
Department of Neurology, Ulm University Hospital, Ulm, Germany
5 shared publications - Markus Otto
Department of Neurology Martin‐Luther‐University Halle‐Wittenberg Halle (Saale) Germany
4 shared publications - Patrick Oeckl
Department of Neurology Ulm University Hospital Ulm Germany
4 shared publications - Eugeen Vanmechelen
ADx NeuroSciences NV, Ghent, Belgium
2 shared publications - Federico Massa
Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), University of Genoa, Genoa, Italy
2 shared publications - Giovanni Bellomo
Section of Neurology, Department of Medicine and Surgery, University of Perugia, Perugia, Italy
2 shared publications
Latest Publications
- Open Access
Aquaporin-4 as an early cerebrospinal fluid biomarker of Alzheimer’s disease
Importance Aquaporin-4 (AQP4) plays a critical role in the glymphatic system, responsible for clearing brain solutes like Aβ peptides. Exploring AQP4 as an Alzheimer’s disease (AD) biomarker might aid in the understanding of AD neuropathology and monitor the effects of novel drug candidates on the glymphatic system. Objective To determine the potential of CSF AQP4 as an early stage AD biomarker using a newly established immunoassay. Design A discovery cohort (n = 157) (2010-2022), composed by AD patients, other neurodegenerative conditions and controls (CON), was used to assess the diagnostic performance of CSF AQP4. Subsequently, AQP4 concentration across the clinical AD spectrum was analyzed in two independent validation cohorts (n = 176) (2016-2023). Stratified randomization based on diagnosis and blinded analyses were performed. Setting Multicenter study: Ulm University Hospital (discovery), University of Perugia (validation cohort I), University Hospital of Torino (validation cohort II). Participants Discovery cohort: 38 CON, 40 AD, 21 primary progressive aphasia, 20 behavioural variant frontotemporal dementia, 17 amyotrophic lateral sclerosis (ALS), and 21 Lewy body disease (LBD). Validation cohorts: 55 CON, 14 preclinical AD, 51 AD with mild cognitive impairment (AD-MCI), 39 AD dementia (ADD) and 17 mild cognitive impairment with non-AD pathology (non-AD MCI). The discovery cohort was selected through random sampling, while validation cohort I and II followed a consecutive sampling method. Exposures CSF AQP4 Main Outcome (s) and Measure (s) AQP4 CSF biomarker detection Results A total of 333 participants were included in this study. In the discovery cohort, the median (IQR) age was 69 (61-75) years and 46.5% of the cohort were women. CSF AQP4 concentration was increased in AD patients compared to CON (p < 0.001), ALS (p = 0.015), and LBD (p = 0.012) patients. CSF AQP4 in AD patients were further analyzed in validation cohort I (median (IQR) age, 74 (71-77) years; 62.0% women), and II (median (IQR) age, 71 (65-75) years; 58.5% women). When analyzing the different stages of the AD continuum in validation cohort I, AD-MCI (p = 0.011) and ADD (p = 0.002) patients had significantly higher AQP4 concentrations than CON. Similar results were obtained in cohort II, where AQP4 levels were higher in AD-MCI (p < 0.001) and ADD (p = 0.028) patients compared to controls. The AQP4 accuracy (area under the receiver operating characteristic curve [AUC]) to distinguish AD patients from CON was 0.81 (95% CI: 0.71 to 0.90, p Conclusions and Relevance Three independent cohorts consistently showed elevated AQP4 levels in AD (including AD-MCI and ADD) compared to CON and other neurodegenerative conditions, suggesting specificity to AD pathology. These findings contribute to understanding AD neuropathology and propose AQP4 as a potential early biomarker of AD. Further investigations are needed to proof AQP4 as a fluid blood brain barrier damage marker. Question Is cerebrospinal fluid (CSF) aquaporin-4 (AQP4) an early Alzheimer’s disease (AD) biomarker? Findings In this cross-sectional study of 333 participants from 3 different cohorts, the CSF concentration of AQP4 was significantly increased in patients with AD, both with mild cognitive impairment (MCI) and dementia, when compared to controls (CON) and other neurodegenerative conditions. Meaning CSF AQP4 is altered in early stages of AD and might be a fluid biomarker for blood brain barrier damage.
Open AccessAquaporin-4 as an early cerebrospinal fluid biomarker of Alzheimer’s disease
Importance Aquaporin-4 (AQP4) plays a critical role in the glymphatic system, responsible for clearing brain solutes like Aβ peptides. Exploring AQP4 as an Alzheimer’s disease (AD) biomarker might aid in the understanding of AD neuropathology and monitor the effects of novel drug candidates on the glymphatic system. Objective To determine the potential of CSF AQP4 as an early stage AD biomarker using a newly established immunoassay. Design A discovery cohort (n = 157) (2010-2022), composed by AD patients, other neurodegenerative conditions and controls (CON), was used to assess the diagnostic performance of CSF AQP4. Subsequently, AQP4 concentration across the clinical AD spectrum was analyzed in two independent validation cohorts (n = 176) (2016-2023). Stratified randomization based on diagnosis and blinded analyses were performed. Setting Multicenter study: Ulm University Hospital (discovery), University of Perugia (validation cohort I), University Hospital of Torino (validation cohort II). Participants Discovery cohort: 38 CON, 40 AD, 21 primary progressive aphasia, 20 behavioural variant frontotemporal dementia, 17 amyotrophic lateral sclerosis (ALS), and 21 Lewy body disease (LBD). Validation cohorts: 55 CON, 14 preclinical AD, 51 AD with mild cognitive impairment (AD-MCI), 39 AD dementia (ADD) and 17 mild cognitive impairment with non-AD pathology (non-AD MCI). The discovery cohort was selected through random sampling, while validation cohort I and II followed a consecutive sampling method. Exposures CSF AQP4 Main Outcome (s) and Measure (s) AQP4 CSF biomarker detection Results A total of 333 participants were included in this study. In the discovery cohort, the median (IQR) age was 69 (61-75) years and 46.5% of the cohort were women. CSF AQP4 concentration was increased in AD patients compared to CON (p < 0.001), ALS (p = 0.015), and LBD (p = 0.012) patients. CSF AQP4 in AD patients were further analyzed in validation cohort I (median (IQR) age, 74 (71-77) years; 62.0% women), and II (median (IQR) age, 71 (65-75) years; 58.5% women). When analyzing the different stages of the AD continuum in validation cohort I, AD-MCI (p = 0.011) and ADD (p = 0.002) patients had significantly higher AQP4 concentrations than CON. Similar results were obtained in cohort II, where AQP4 levels were higher in AD-MCI (p < 0.001) and ADD (p = 0.028) patients compared to controls. The AQP4 accuracy (area under the receiver operating characteristic curve [AUC]) to distinguish AD patients from CON was 0.81 (95% CI: 0.71 to 0.90, p Conclusions and Relevance Three independent cohorts consistently showed elevated AQP4 levels in AD (including AD-MCI and ADD) compared to CON and other neurodegenerative conditions, suggesting specificity to AD pathology. These findings contribute to understanding AD neuropathology and propose AQP4 as a potential early biomarker of AD. Further investigations are needed to proof AQP4 as a fluid blood brain barrier damage marker. Question Is cerebrospinal fluid (CSF) aquaporin-4 (AQP4) an early Alzheimer’s disease (AD) biomarker? Findings In this cross-sectional study of 333 participants from 3 different cohorts, the CSF concentration of AQP4 was significantly increased in patients with AD, both with mild cognitive impairment (MCI) and dementia, when compared to controls (CON) and other neurodegenerative conditions. Meaning CSF AQP4 is altered in early stages of AD and might be a fluid biomarker for blood brain barrier damage.
- Open Access
Quantification of blood glial fibrillary acidic protein using a second-generation microfluidic assay. Validation and comparative analysis with two established assays
Background: Increased levels of glial fibrillary acidic protein (GFAP) in blood have been identified as a valuable biomarker for some neurological disorders, such as Alzheimer’s disease and multiple sclerosis. However, most blood GFAP quantifications so far were performed using the same bead-based assay, and to date a routine clinical application is lacking. Methods: In this study, we validated a novel second-generation (2 nd gen) Ella assay to quantify serum GFAP. Furthermore, we compared its performance with a bead-based single molecule array (Simoa) and a homemade blood GFAP assay in a clinical cohort of neurological diseases, including 210 patients. Results: Validation experiments resulted in an intra-assay variation of 10%, an inter-assay of 12%, a limit of detection of 0.9 pg/mL, a lower limit of quantification of 2.8_pg/mL, and less than 20% variation in serum samples exposed to up to five freeze-thaw cycles, 120_hours at 4 °C and room temperature. Measurement of the clinical cohort using all assays revealed the same pattern of GFAP distribution in the different diagnostic groups. Moreover, we observed a strong correlation between the 2 nd gen Ella and Simoa (r=0.91 (95% CI: 0.88 - 0.93), pnd gen Ella assay. Although a higher assay sensitivity for Simoa was observed, the new microfluidic assay might have the potential to be used for GFAP analysis in daily clinical workups due to its robustness and ease of use. What is already known on this topic: Blood glial fibrillary acidic protein (GFAP) levels are an emerging biomarker for diagnosing, prognosis and treatment monitoring for AD, MS and other neurological disorders. However, so far, the application in clinical routine remains a challenge. What this study adds: This study validated a novel, easy-to-use second-generation microfluidic assay for the quantitative measurement of blood GFAP. Moreover, its performance was compared to two other GFAP immunoassays, including single molecule array. How this study might affect research, practice or policy: This study proved the reliability, precision and reproducibility of the novel second-generation microfluidic assay, which might be more easily implemented in daily clinical routine analyses and therefore facilitates the application of GFAP as a biomarker for neurological diseases.
Open AccessQuantification of blood glial fibrillary acidic protein using a second-generation microfluidic assay. Validation and comparative analysis with two established assays
Background: Increased levels of glial fibrillary acidic protein (GFAP) in blood have been identified as a valuable biomarker for some neurological disorders, such as Alzheimer’s disease and multiple sclerosis. However, most blood GFAP quantifications so far were performed using the same bead-based assay, and to date a routine clinical application is lacking. Methods: In this study, we validated a novel second-generation (2 nd gen) Ella assay to quantify serum GFAP. Furthermore, we compared its performance with a bead-based single molecule array (Simoa) and a homemade blood GFAP assay in a clinical cohort of neurological diseases, including 210 patients. Results: Validation experiments resulted in an intra-assay variation of 10%, an inter-assay of 12%, a limit of detection of 0.9 pg/mL, a lower limit of quantification of 2.8_pg/mL, and less than 20% variation in serum samples exposed to up to five freeze-thaw cycles, 120_hours at 4 °C and room temperature. Measurement of the clinical cohort using all assays revealed the same pattern of GFAP distribution in the different diagnostic groups. Moreover, we observed a strong correlation between the 2 nd gen Ella and Simoa (r=0.91 (95% CI: 0.88 - 0.93), pnd gen Ella assay. Although a higher assay sensitivity for Simoa was observed, the new microfluidic assay might have the potential to be used for GFAP analysis in daily clinical workups due to its robustness and ease of use. What is already known on this topic: Blood glial fibrillary acidic protein (GFAP) levels are an emerging biomarker for diagnosing, prognosis and treatment monitoring for AD, MS and other neurological disorders. However, so far, the application in clinical routine remains a challenge. What this study adds: This study validated a novel, easy-to-use second-generation microfluidic assay for the quantitative measurement of blood GFAP. Moreover, its performance was compared to two other GFAP immunoassays, including single molecule array. How this study might affect research, practice or policy: This study proved the reliability, precision and reproducibility of the novel second-generation microfluidic assay, which might be more easily implemented in daily clinical routine analyses and therefore facilitates the application of GFAP as a biomarker for neurological diseases.
- Open Access
- 7 August 2023
- Published by Elsevier in Molecular & Cellular Proteomics
- Vol. 22 (10) , 100629
Methods to Discover and Validate Biofluid-Based Biomarkers in Neurodegenerative Dementias
- 7 August 2023
- Published by Elsevier in Molecular & Cellular Proteomics
- Vol. 22 (10) , 100629
Open AccessMethods to Discover and Validate Biofluid-Based Biomarkers in Neurodegenerative Dementias
- 17 October 2022
- Published by Elsevier in Journal of Psychiatric Research
- Vol. 156, 390-397
Glutamate receptor 4 as a fluid biomarker for the diagnosis of psychiatric disorders
- 17 October 2022
- Published by Elsevier in Journal of Psychiatric Research
- Vol. 156, 390-397
Glutamate receptor 4 as a fluid biomarker for the diagnosis of psychiatric disorders
- 16 May 2022
- Published by Elsevier in Neurobiology of Aging
- Vol. 117, 212-221
Exploring the brain metabolic correlates of process-specific CSF biomarkers in patients with MCI due to Alzheimer's disease: preliminary data
- 16 May 2022
- Published by Elsevier in Neurobiology of Aging
- Vol. 117, 212-221
Exploring the brain metabolic correlates of process-specific CSF biomarkers in patients with MCI due to Alzheimer's disease: preliminary data
- Open Access
- 30 August 2021
- Published by Springer Nature in Journal of Neural Transmission
- Vol. 129 (2) , 207-230
Neuronal pentraxins as biomarkers of synaptic activity: from physiological functions to pathological changes in neurodegeneration
The diagnosis of neurodegenerative disorders is often challenging due to the lack of diagnostic tools, comorbidities and shared pathological manifestations. Synaptic dysfunction is an early pathological event in many neurodegenerative disorders, but the underpinning mechanisms are still poorly characterised. Reliable quantification of synaptic damage is crucial to understand the pathophysiology of neurodegeneration, to track disease status and to obtain prognostic information. Neuronal pentraxins (NPTXs) are extracellular scaffolding proteins emerging as potential biomarkers of synaptic dysfunction in neurodegeneration. They are a family of proteins involved in homeostatic synaptic plasticity by recruiting post-synaptic receptors into synapses. Recent research investigates the dynamic changes of NPTXs in the cerebrospinal fluid (CSF) as an expression of synaptic damage, possibly related to cognitive impairment. In this review, we summarise the available data on NPTXs structure and expression patterns as well as on their contribution in synaptic function and plasticity and other less well-characterised roles. Moreover, we propose a mechanism for their involvement in synaptic damage and neurodegeneration and assess their potential as CSF biomarkers for neurodegenerative diseases.
- 30 August 2021
- Published by Springer Nature in Journal of Neural Transmission
- Vol. 129 (2) , 207-230
Open AccessNeuronal pentraxins as biomarkers of synaptic activity: from physiological functions to pathological changes in neurodegeneration
The diagnosis of neurodegenerative disorders is often challenging due to the lack of diagnostic tools, comorbidities and shared pathological manifestations. Synaptic dysfunction is an early pathological event in many neurodegenerative disorders, but the underpinning mechanisms are still poorly characterised. Reliable quantification of synaptic damage is crucial to understand the pathophysiology of neurodegeneration, to track disease status and to obtain prognostic information. Neuronal pentraxins (NPTXs) are extracellular scaffolding proteins emerging as potential biomarkers of synaptic dysfunction in neurodegeneration. They are a family of proteins involved in homeostatic synaptic plasticity by recruiting post-synaptic receptors into synapses. Recent research investigates the dynamic changes of NPTXs in the cerebrospinal fluid (CSF) as an expression of synaptic damage, possibly related to cognitive impairment. In this review, we summarise the available data on NPTXs structure and expression patterns as well as on their contribution in synaptic function and plasticity and other less well-characterised roles. Moreover, we propose a mechanism for their involvement in synaptic damage and neurodegeneration and assess their potential as CSF biomarkers for neurodegenerative diseases.